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Introduction
Dementia is an acquired impairment of intellectual function, af-
fecting at least three out of six spheres of mental activity: lan-
guage, memory, visuospatial skills, emotion, personality and cog-
nition. Dementia may be divided into global dementia, when all
intellectual functions are more or less randomly impaired and la-
cunar dementia with more selective functional impairment. The
aetiology of dementia is complex. Dementia may be of neurode-
generative origin, vascular origin or may be so called reversible
dementia, due to the factors like vitamin deficiency, chronic sub-
dural hematoma, circulatory insufficiency and others.
The crucial factor in the diagnosis and management of de-
mentia is the correct identification of underlying cause. In Alzhe-
imers disease (AD) early diagnosis is important not only for the
purpose of prognostication and family counselling, but also it may
provide medication of AD patient with some, more or less promis-
ing experimental drug trials. Additionally, establishing or exclud-
ing diagnosis of AD will stabilise the position of family members,
who will be not left for prolonged financial and emotional draining.
Certain other disorders, accompanying and/or mimicking signs
of dementia like major depression or cerebrovascular diseases
may be treated for stopping, slowing down or sometimes revers-
ing the course of dementia.
An important aid in the differential diagnosis of dementia is
cerebral blood flow brain (CBF) SPECT scanning. Although the
sole use of neuroimaging methods should not allow to establish
the final diagnosis, CBF SPECT scanning may improve diagnos-
tic precision and may help to diagnose dementias of different types
 above all  AD. The widely available brain SPECT examination
versus the more limited availability of PET may have a key role in
diagnosis and staging of dementia severity.
The aim of this paper is to overview cerebral blood flow chang-
es in particular types of dementia and the applications of brain
SPECT in this group of diseases.
Alzheimers disease
Alzheimer disease (AD) is considered the most common neuro-
degenerative disorder, about 3060% of dementia cases, although
in common practice the diagnosis of AD happens to be overuti-
lised. For example, a vascular infarct of temporal lobe may pro-
duce signs resembling AD. The onset of AD is insidious, the first
symptoms are the difficulties in remembering names and recent
memory problems. The course of disease is characterised by
steadily progressive cognitive impairment with lack of motor and
neurologic signs (1). Neurofibrillary tangles and neuritic plaques
are typical pathological finding in AD. In early stage of AD  neuro-
degenerative changes are found in the limbic system, particularly
in hippocampus, a structure playing an important role in recent
memory processing (2). In later stages of disease those changes
are found mostly in temporoparietal lobes, which is consistent
with CBF changes.
The main SPECT finding is a symmetric drop of rCBF starting
in the mesial part of temporal lobe, then spreading on the rest of
temporal lobe and parietal lobes. Temporo-parietal hypoperfusion
is considered to be the most outstanding feature of CBF alter-
ations in AD. Cerebellum, motor and visual cortex is spared (3).
There are two difficulties with radionuclide evaluating of AD:
 temporoparietal perfusion deficit is not entirely specific for AD;
it may be found in dementia with Lewy bodies  DLB (4), in
mitochondria encephalopathy (5) and monoxide poisoning (6);
two latter situations, however, may be confirmed or excluded
on a basis of case history and clinical data;
 secondly, AD is heterogenous disease and this heterogeneity
is reflected in SPECT studies (7); temporoparietal deficit is not
found in all patients with AD and this is suggested that this
neuroimaging finding may be helpful in differentiating subtypes
of AD (8); furthermore, reduced frontal glucose metabolism
and blood flow impairment has been reported in some stud-
ies (9, 10); those findings may however reflect unrecognised
LBD and not AD.
The crucial problem of rCBF SPECT scanning in AD is fact
that although its sensitivity in advanced disease is about 7080%,
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in early stages SPECTs sensitivity is lower. This may be solved by
careful evaluation of early hippocampal changes or by image anal-
ysis standardisation, for example as proposed by Imran et al. (11).
Another use of rCBF SPECT may be its use as a marker of the
effects of pharmacotherapy (12).
Dementia with Lewy bodies
Dementia with Lewy bodies (DLB) is considered to be the second
most common senile degenerative dementia after AD (13). The
central clinical feature of DLB is a progressive and fluctuating cog-
nitive decline with recurrent visual hallucinations, systematised
delusions and spontaneous parkinsonian symptom. Repeated
falls, syncope, transient loss of consciousness and neuroleptic
sensitivity are also useful clinical characteristics (14). When the
initial presentation of DLB is characterised by impaired cognition
it can mimic AD (15). Furthermore, neuropsychological evalua-
tion can disclose severe but similar degrees of impaired perfor-
mances concerning attention, frontal lobe function and motor func-
tion sequencing in both DLB and AD (16). Pathological study re-
mains the only way to confirm the diagnosis of DLB, when evi-
dence of Lewy bodies is found in the cortex, the subcortical re-
gions and the brain stem (substantia nigra and locus coeruleus)
(17). The precise nosological relationship of DLD and AD is still a
matter of debate. On one hand common clinical and pathological
features of DLB and AD are observed, so some authors consider
DLB to be a variant of AD; on the other hand some authors con-
sider the two diseases independent, with DLB seen as a more
extended form of idiopathic Parkinsons disease  IDB (18).
Early diagnosis is an important problem in DLB. Cholinergic
deficit in DLB is more extensive when compared with AD. This
explains the beneficial effect of therapy with cholinesterase inhib-
itors, with improvement of cognitive function (19).
In DLB SPECT scanning reveals a global decrease of cerebral
blood flow in all cortical regions except posterior part of frontal
lobes and occipital regions (4, 20). This could be a marker of dis-
ease, distinguishing DLB from AD where a posterior half of the
brain is affected by CBF alterations and FTLD where the anterior
half is affected. The diffuse decrease of blood flow observed in
DLB suggests widespread lesions in the cortex, which is consis-
tent with pathological studies. Lewy bodies are observed in many
cortical structures: especially in frontal, insular and temporal cor-
tex and in anterior cingulate (15). Some authors underline the oc-
currence of occipital hypoperfusion and/or hypometabolism and
recommend it as the marker of DLB (21). The crucial point in DLB
SPECT studies is that definite diagnosis of DLB can be estab-
lished at post-mortem studies, so most of papers refer to patients
with probable, but not fully established diagnosis of DLB.
Frontotemporal lobar degeneration
The term frontotemporal lobar degeneration (FTD) is a concept
delineated independently by Neary (22) and Gustafson (23). It is
a group of neurodegenerative disorders characterised by progres-
sive changes of social conduct, poor insight, poor hygiene and
disinhibition. Spontaneous speech becomes increasingly econom-
ical with disease progression, culminating in mutism in some pa-
tients. By contrast, visuospatial and motor functions are preserved
and neurological examination is usually normal. Sometimes this
examination may reveal frontal lobe release phenomena. The cri-
terions for diagnosis of FTD were summarised in 1994 by Brun et
al. (24). In contrast to AD in which memory loss is early, FTD may
lack this feature. FTD accounts for 1015% of all dementias with
Picks disease as a subtype of FTD accounting only for 1% of
dementias.
In FTD brain SPECT is an established diagnostic criterion. CBF
changes are most pronounced in anterior half of the brain in con-
trast to AD, where a posterior half is involved (22, 23, 24). Frontal
hypoperfusion may be however an unspecific finding as it can be
met in schizophrenia (25), chronic alcohol abuse (26) or as paral-
lel to multiple cerebral infarctions (27).
Progressive aphasia
In progressive aphasia patients present with progressive disorder
of speech.  Spontaneous speech is non-fluent and effortful, con-
taining literal paraphasias. Word finding difficulty is one of most
considerable phenomenons. Comprehension, although usually
may be preserved, is eventually affected late in the disease pro-
gression. Visuospatial and motor function is usually preserved and
neurological examination normal, sometimes showing frontal re-
lease phenomena. Brain CT is either normal or shows cortical at-
rophy of diverse degree (28).
SPECT findings in progressive aphasia are not entirely specif-
ic. Unilateral, left-sided posterior CBF decrease is considered to
be the most frequent finding and significantly increases the odds
of patient having progressive aphasia as opposed to other forms
of dementia (29, 30).
Vascular dementias
Vascular diseases that may cause dementia include multiple cor-
tical infarcts, single cortical infarct in strategic location (e.g. hip-
pocampus) and small vessels disease (31). Those patients usu-
ally exhibit deficits in at least two cognitive domains indicative of
cortical or subcortical dysfunctions (32). This may be accompa-
nied by focal neurological signs suggestive of cerebrovascular
disease such as hemianopia, dysarthria, hemisensory deficit, hemi-
paresis or Babinski sign. Brain CT shows multiple large vessels
infarcts or multiple cortical infarcts and/or periventricular lucency.
The typical SPECT feature of multi-infarct dementia (MID) are
asymmetrically distributed multifocal CBF deficits, also called
patchy changes (30, 33). On one hand CT and MRI should play
an essential role in identifying cortical infarcts because of better
spatial resolution, on the other SPECT may prove superior in de-
picting multifocal cerebrovascular insufficiency, which was seen
in patients with collagen tissue diseases (34), terminal renal le-
sion (35) and head trauma (36). MRI scanning may moreover
detect white unspecific matter hyperintensities also in asymptom-
atic, healthy elderly people (37). For the differential diagnosis of
neurodegenerative disease vs. vascular insufficiency may be useful
stress test with acetazolamide, revealing areas of hypoperfusion
not seen in baseline study and augmenting ones little visible in
baseline study (38). In vascular dementia acetazolamide test re-
veals three-fold decreased reserve blood flow capacity in com-
parison with AD (39).
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The crucial point in diagnosing multi-vascular lesion using
SPECT scanning is the possibility of co-existence of cortical inf-
arcts and neurodegenerative diseases, especially in older patients.
Here fusion of SPECT/CT/MRI data may be a compromise lead-
ing to the correct diagnosis.
Reversible dementias
Reversible dementias is a group of disorders usually secondary
to the other diseases either directly affecting the brain or with its
extra-CNS localisation. This includes brain tumours, chronic sub-
dural hematoma, communicating hydrocephalus, hepatic enceph-
alopathy, chronic alcoholism, hypothyroidism, insulinoma, vitamin
deficiencies, sarcoidosis, syphilis, giant-cells arteritis, chronic in-
toxications, adverse drug reactions. Some of those changes are
hardly reversible, therefore potentially reversible dementias
seems to be the more correct description. Also primary depres-
sions may mimic dementia.
For most of those disorders frontal hypoperfusion is a marker.
In primary depression also paralimbic hypoperfusion is a typical
finding (40). In contrast to FTD CBF changes in depression may
improve in course of therapy , whereas that of FTD worsens in
time.
Follow-up CBF SPECT scanning in dementia
Follow up SPECT scanning may prove valuable in two situations:
differentiation of neurodegenerative and vascular disorders, where
SPECT changes usually are progressive (41) and cognitive disor-
ders secondary to depression, where the treatment leads to per-
fusion improvement.
Synthesis
Perhaps the best neurologists point of view synthesis of the above
was given by Talbot and co-workers in 1998 (30). They proposed
the following approach: 99mTc-HMPAO SPECT is most useful in
distinguishing Alzheimers disease from vascular dementia and
fronto-temporal dementia; least useful in differentiating between
Alzheimers disease and Lewy body disease; also least useful in
differentiating  between vascular dementia, fronto-temporal de-
mentia and progressive aphasia. Therefore, in those authors opin-
ion CBF SPECT should be used selectively and as adjunct to clin-
ical evaluation and CT. As a summary of considerations given
above the most typical  CBF changes in dementia of diverse ori-
gin are showed in a table below (Table 1).
Conclusions
CBF SPECT provides a valuable contribution in the clinical differ-
entiation of dementia. It provides information that is useful for the
clinician in the interpretation of individual tests. CBF abnormali-
ties are not specific to a single disease, so its role is an adjunct to
clinical evaluation. However, due to its functional character CBF
SPECT scanning usually provides more valuable information than
CT and MRI and SPECTs application in dementia is one of the
most important aims in a routine work of nuclear medicine depart-
ment.
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